L
Larissa Felt
Publications - 5
Citations - 219
Larissa Felt is an academic researcher. The author has contributed to research in topics: Dyskinesia & Placebo. The author has an hindex of 4, co-authored 5 publications receiving 171 citations.
Papers
More filters
Journal ArticleDOI
Randomized, placebo-controlled trial of ADS-5102 (amantadine) extended-release capsules for levodopa-induced dyskinesia in Parkinson's disease (EASE LID 3).
Wolfgang H. Oertel,Karla Eggert,Rajesh Pahwa,Caroline M. Tanner,Robert A. Hauser,Claudia Trenkwalder,Reinhard Ehret,Jean-Philippe Azulay,Stuart Isaacson,Larissa Felt,Mary Jean Stempien +10 more
TL;DR: The treatment of levodopa‐induced dyskinesia in Parkinson's disease is an unmet need with no approved drug therapy.
Journal ArticleDOI
Pooled Analyses of Phase III Studies of ADS-5102 (Amantadine) Extended-Release Capsules for Dyskinesia in Parkinson's Disease
Lawrence Elmer,Jorge L. Juncos,Carlos Singer,Daniel D. Truong,Susan R. Criswell,Sotirios A. Parashos,Larissa Felt,Reed Johnson,Rajiv Patni +8 more
TL;DR: For both efficacy measures, a significant difference from placebo was attained by two weeks, the first post-baseline assessment, and was maintained throughout 12 weeks, providing further evidence supporting ADS-5102 as an adjunct to levodopa for treating both dyskinesia and OFF time in PD patients with dysKinesia.
Journal ArticleDOI
ADS-5102 (Amantadine) Extended-Release Capsules for Levodopa-Induced Dyskinesia in Parkinson's Disease (EASE LID 2 Study): Interim Results of an Open-Label Safety Study.
Robert A. Hauser,Rajesh Pahwa,Caroline M. Tanner,Wolfgang H. Oertel,Stuart Isaacson,Reed Johnson,Larissa Felt,Mary Jean Stempien +7 more
TL;DR: ADS-5102 was generally well tolerated in all groups, including DBS patients, and the safety profile was consistent with previous controlled studies.
Journal ArticleDOI
Author Correction to: Pooled Analyses of Phase III Studies of ADS-5102 (Amantadine) Extended-Release Capsules for Dyskinesia in Parkinson’s Disease
Lawrence Elmer,Jorge L. Juncos,Carlos Singer,Daniel D. Truong,Susan R. Criswell,Sotirios A. Parashos,Larissa Felt,Reed Johnson,Rajiv Patni +8 more
TL;DR: An Online First version of this article was made available online at http://link.springer.com/journal/40263/onlineFirst/page/1 on 12 March 2018 and an error was subsequently identified in the article, and the following correction should be noted.
Journal Article
A Clinically Important Difference (CID) for the Unified Dyskinesia Rating Scale (UDysRS) Total Score Change in Parkinson’s Disease (PD) Patients with Dyskinesia (P2.052)
Rajesh Pahwa,Caroline M. Tanner,Caroline M. Tanner,Robert A. Hauser,Stuart Isaacson,Reed Johnson,Larissa Felt,Rajiv Patni,Lily Llorens +8 more
TL;DR: It is suggested that a decrease of at least 9 units in the UDysRS is a CID which is consistent with at least minimal improvements in the CGI-C, respectively.